Avenue Therapeutics (ATXI) has disclosed a new risk, in the Regulation category.
Avenue Therapeutics faces substantial regulatory challenges due to its development of IV Tramadol, a controlled substance. The intricate web of state, federal, and foreign laws, notably the CSA and DEA regulations, necessitates stringent compliance for manufacture, distribution, and sale. State-level discrepancies in scheduling and regulation could delay or limit market access, even after federal approval. Non-compliance risks include severe penalties, jeopardizing Avenue Therapeutics’ operational and financial prospects.
Overall, Wall Street has a Moderate Buy consensus rating on ATXI stock based on 1 Buy.
To learn more about Avenue Therapeutics’ risk factors, click here.
